CERo Therapeutics Holdings Inc

CERO

Company Profile

  • Business description

    CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

  • Contact

    201 Haskings Way
    Suite 230
    South San FranciscoCA94080
    USA

    T: +1 650 407-2376

    https://www.cero.bio

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    8

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.4015.50-0.18%
CAC 407,723.4727.200.35%
DAX 4024,073.67286.221.20%
Dow JONES (US)44,406.36422.17-0.94%
FTSE 1008,806.5316.38-0.19%
HKSE23,887.8328.23-0.12%
NASDAQ20,412.52188.59-0.92%
Nikkei 22539,587.68223.20-0.56%
NZX 50 Index12,755.749.21-0.07%
S&P 5006,229.9849.37-0.79%
S&P/ASX 2008,589.3013.70-0.16%
SSE Composite Index3,473.130.810.02%

Market Movers